Quantum Biopharma Ltd (QNTM)

$6.30 +0.06 (0.96%)
Market Cap 12.09M
Revenue (ttm) 0.00
Net Income (ttm) -14.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,400
Avg Vol 1,515,822
Day's Range N/A - N/A
Shares Out 1.92M
Stochastic %K 31%
Beta 0.00
Analysts Sell
Price Target $12.80

Latest News on QNTM

Quantum BioPharma Corporate Update

Apr 18, 2025, 8:00 PM EDT - 1 day ago

Quantum BioPharma Corporate Update

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

Apr 14, 2025, 7:30 AM EDT - 5 days ago

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico

Apr 3, 2025, 7:00 AM EDT - 16 days ago

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Apr 1, 2025, 2:00 AM EDT - 19 days ago

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms

Mar 31, 2025, 7:00 AM EDT - 19 days ago

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms

Quantum BioPharma Provides Corporate Update

Mar 30, 2025, 7:00 PM EDT - 20 days ago

Quantum BioPharma Provides Corporate Update

Overlooked Stock: QNTM

Mar 28, 2025, 4:38 PM EDT - 22 days ago

Overlooked Stock: QNTM

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Mar 28, 2025, 9:15 AM EDT - 22 days ago

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies

Mar 20, 2025, 7:30 AM EDT - 4 weeks ago

Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies

Quantum BioPharma Unaware of Any Material Change

Mar 17, 2025, 3:33 PM EDT - 4 weeks ago

Quantum BioPharma Unaware of Any Material Change

Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Feb 11, 2025, 7:30 AM EST - 2 months ago

Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs

Feb 10, 2025, 7:30 AM EST - 2 months ago

Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study

Feb 6, 2025, 7:30 AM EST - 2 months ago

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial

Feb 4, 2025, 7:03 AM EST - 2 months ago

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial

Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

Jan 17, 2025, 7:30 AM EST - 3 months ago

Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

Jan 14, 2025, 8:30 AM EST - 3 months ago

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM

Quantum Biopharma Ltd. Approved to Dual List on Upstream

Jan 7, 2025, 8:30 AM EST - 3 months ago

Quantum Biopharma Ltd. Approved to Dual List on Upstream

Quantum Biopharma Announces Closing of Second Tranche

Dec 20, 2024, 7:30 PM EST - 4 months ago

Quantum Biopharma Announces Closing of Second Tranche

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

Dec 20, 2024, 9:15 AM EST - 4 months ago

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

Dec 20, 2024, 7:30 AM EST - 4 months ago

Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency

Quantum Biopharma Announces Closing of First Tranche

Dec 13, 2024, 7:00 PM EST - 4 months ago

Quantum Biopharma Announces Closing of First Tranche

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)

Dec 10, 2024, 7:30 AM EST - 4 months ago

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million

Dec 5, 2024, 7:30 AM EST - 4 months ago

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

Nov 25, 2024, 7:00 AM EST - 5 months ago

Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

Oct 29, 2024, 7:30 AM EDT - 6 months ago

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma

Oct 28, 2024, 11:10 AM EDT - 6 months ago

Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma

Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma

Oct 23, 2024, 9:30 AM EDT - 6 months ago

Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Oct 22, 2024, 7:00 AM EDT - 6 months ago

Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Oct 21, 2024, 9:30 AM EDT - 6 months ago

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Oct 21, 2024, 7:00 AM EDT - 6 months ago

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America

Oct 7, 2024, 8:40 AM EDT - 6 months ago

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America

Oct 7, 2024, 7:30 AM EDT - 6 months ago

Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America

Quantum Biopharma Provides Corporate Update

Sep 27, 2024, 8:06 PM EDT - 7 months ago

Quantum Biopharma Provides Corporate Update

Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US

Sep 25, 2024, 9:20 AM EDT - 7 months ago

Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US

Quantum BioPharma Closes Private Placement Offering

Sep 13, 2024, 8:00 PM EDT - 7 months ago

Quantum BioPharma Closes Private Placement Offering

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

Sep 9, 2024, 7:30 AM EDT - 7 months ago

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements

Sep 6, 2024, 7:30 PM EDT - 8 months ago

Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"

Aug 30, 2024, 7:30 AM EDT - 8 months ago

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

Aug 23, 2024, 7:30 PM EDT - 8 months ago

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update